Publication | Open Access

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

First-line ChemotherapySwitch-maintenance GemcitabineMalignant DiseaseMedicineMalignant MesotheliomaCancer TreatmentRadiation OncologyOncologyCancer ChemotherapyRadiologyHealth Sciences